A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia
Ricardo D Parrondo, Sikander Ailawadhi, Betsy R Knopf, Ashley Zimmerman, Carly J Kasik, Dustin Chapin, Keisha Heslop, Vivek Roy, Aneel Paulus, Asher A Chanan-Khan · 2026
Read A phase II study of daratumumab and ibrutinib for relapsed/refractory chronic lymphocytic leukemia by Ricardo D Parrondo, Sikander Ailawadhi, Betsy R Knopf, Ashley Zimmerman, Carly J Kasik, Dustin Chapin, Keisha Heslop, Vivek Roy, Aneel Paulus, Asher A Chanan-Khan (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13153351.txt.
Description
Ricardo Parrondo and co-authors set out a phase two study of two drugs for a blood cancer that has come back or stopped responding. The report appeared in 2026. New targeted drugs have raised survival in this disease over the past ten years. Still, many patients grow resistant to the first drugs over time.
The study pairs a drug that blocks a growth switch with an antibody that targets a marker on the cancer cells. Lab work showed the antibody can kill cancer cells and shift immune cells toward attack. High levels of the marker have been tied to more bold growth and worse results. The trial tests whether the pair can help after other drugs fail.
Catalog record
| CREATOR | Ricardo D Parrondo, Sikander Ailawadhi, Betsy R Knopf, Ashley Zimmerman, Carly J Kasik, Dustin Chapin, Keisha Heslop, Vivek Roy, Aneel Paulus, Asher A Chanan-Khan |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 13 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |